Metformin, but not rosiglitazone, attenuates the increasing plasma levels of a new cardiovascular marker, Fibulin-1, in patientswith Type 2 diabetes

Diabetes Care

Volumn 37, Issue 3, 2014, Pages 760-766

  Skov, Vibe ^a   Cangemi, Claudia ^a   Gram, Jeppe ^b   Christensen, Mette M ^c   Grodum, Ellen ^d   Sørensen, Ditte ^a   Argraves, W Scott ^e   Henriksen, Jan E ^a   Rasmussen, Lars M ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b ESBJERG HOSPITAL   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d Fredericia Sygehus   (Denmark)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FIBULIN; FIBULIN 1; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; ISOPHANE INSULIN; METFORMIN; PLACEBO; ROSIGLITAZONE; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CALCIUM BINDING PROTEIN; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CLINICAL INDICATOR; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); WEIGHT GAIN; BLOOD; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG COMBINATION; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; UPREGULATION;

ADULT; AGED; BIOMARKERS; BLOOD GLUCOSE; CALCIUM-BINDING PROTEINS; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; PROSPECTIVE STUDIES; THIAZOLIDINEDIONES; UP-REGULATION;

EID: 84896690343     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-1022     Document Type: Article

References (43)

1. Bonow RO, Gheorghiade M. The diabetes epidemic: a national and global crisis. Am J Med 2004;116(Suppl. 5A):2S-10S
2. Adler AI. UKPDS-modelling of cardiovascular risk assessment and lifetime simulation of outcomes. Diabet Med 2008; 25(Suppl. 2):41-46
3. Group UKPDS; UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713
4. Shepherd J, Barter P, Carmena R, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006;29:1220-1226
5. Preis SR, Pencina MJ, Hwang SJ, et al. Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study. Circulation 2009;120:212-220
6. Group UKPDS; UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352:854-865
7. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
8. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574-579
9. Bailey CJ. Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc Drugs Ther 2008;22: 215-224
10. Hong J, Zhang Y, Lai S, et al.; SPREADDIMCAD Investigators. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 2013;36:1304-1311
11. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001;37:1344-1350
12. Abbasi F, Chu JW, McLaughlin T, Lamendola C, Leary ET, Reaven GM. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism 2004;53:159-164
13. De Jager J, Kooy A, Lehert P, et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med 2005;257:100-109
14. Davis BJ, Xie Z, Viollet B, Zou MH. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes 2006;55:496-505
15. Kooy A, de Jager J, Lehert P, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 2009;169:616-625
16. Lund SS, Tarnow L, Stehouwer CD, et al. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. Eur J Endocrinol 2008;158: 631-641
17. Skov V, Knudsen S, Olesen M, Hansen ML, Rasmussen LM. Global gene expression profiling displays a network of dysregulated genes in non-atherosclerotic arterial tissue from patients with type 2 diabetes. Cardiovasc Diabetol 2012;11:15
18. Cangemi C, Skov V, Poulsen MK, et al. Fibulin-1 is a marker for arterial extracellular matrix alterations in type 2 diabetes. Clin Chem 2011;57:1556-1565
19. Scholze A, Bladbjerg EM, Sidelmann JJ, et al. Plasma concentrations of extracellular matrix protein fibulin-1 are related to cardiovascular risk markers in chronic kidney disease and diabetes. Cardiovasc Diabetol 2013;12:6
20. Chan MY, Lin M, Lucas J, et al. Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anticoagulation with warfarin or a direct factor Xa inhibitor. Thromb Haemost 2012;108: 1180-1191
21. Kaur P, Rizk NM, Ibrahim S, et al. iTRAQbased quantitative protein expression profiling and MRM verification of markers in type 2 diabetes. J Proteome Res 2012;11: 5527-5539
22. Timpl R, Sasaki T, Kostka G, Chu ML. Fibulins: a versatile family of extracellular matrix proteins. Nat Rev Mol Cell Biol 2003; 4:479-489
23. Argraves WS, Dickerson K, Burgess WH, Ruoslahti E. Fibulin, a novel protein that interacts with the fibronectin receptor beta subunit cytoplasmic domain. Cell 1989;58: 623-629
24. Argraves WS, Tran H, Burgess WH, Dickerson K. Fibulin is an extracellular matrix and plasma glycoprotein with repeated domain structure. J Cell Biol 1990; 111:3155-3164
25. Kostka G, Giltay R, Bloch W, et al. Perinatal lethality and endothelial cell abnormalities in several vessel compartments of fibulin-1-deficient mice. Mol Cell Biol 2001;21:7025-7034
26. Cooley MA, Kern CB, Fresco VM, et al. Fibulin-1 is required for morphogenesis of neural crest-derived structures. Dev Biol 2008;319:336-345
27. Gram J, Henriksen JE, Grodum E, et al. Pharmacological treatment of the pathogenetic defects in type 2 diabetes: the randomized multicenter South Danish Diabetes Study. Diabetes Care 2011;34:27-33
28. Christensen MM, Brasch-Andersen C, Green H, et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics 2011;21:837-850
29. Nathan DM, Buse JB, Davidson MB, et al.; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
30. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002;25:2244-2248
31. Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011;32: 1900-1908
32. Derosa G, Maffioli P. Peroxisome proliferator-activated receptor-g (PPAR-g) agonists on glycemic control, lipid profile and cardiovascular risk. Curr Mol Pharmacol 2012;5:272-281
33. Plutzky J. Macrovascular effects and safety issues of therapies for type 2 diabetes. Am J Cardiol 2011;108(Suppl.):25B-32B
34. Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ 2011;342:d1309
35. Romualdi D, Costantini B, Selvaggi L, et al. Metformin improves endothelial function in normoinsulinemic PCOS patients: a new prospective. Hum Reprod 2008;23:2127-2133
36. Burl ́a AK, Lobato NS, Fortes ZB, Oigman W, Neves MF. Cardiac fibrosis and vascular remodeling are attenuated by metformin in obese rats. Int J Cardiol 2013;165:483-487
37. Sena CM, Matafome P, Louro T, Nunes E, Fernandes R, Seiça RM.Metformin restores endothelial function in aorta of diabetic rats. Br J Pharmacol 2011;163:424-437
38. Xie Z, Zhang J, Wu J, Viollet B, Zou MH. Upregulation of mitochondrial uncoupling protein-2 by the AMP-activated protein kinase in endothelial cells attenuates oxidative stress in diabetes. Diabetes 2008; 57:3222-3230
39. Isoda K, Young JL, Zirlik A, et al. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol 2006;26:611-617
40. Ling Y,Maile LA, Badley-Clarke J, Clemmons DR. DOK1 mediates SHP-2 binding to the alphaVbeta3 integrin and thereby regulates insulin-like growth factor I signaling in cultured vascular smooth muscle cells. J Biol Chem 2005;280:3151-3158
41. Mittermayer F, Schaller G, Pleiner J, et al. Rosiglitazone prevents free fatty acidinduced vascular endothelial dysfunction. J Clin Endocrinol Metab 2007;92:2574-2580
42. Nybo M, Preil SR, Juhl HF, et al. Rosiglitazone decreases plasma levels of osteoprotegerin in a randomized clinical trial with type 2 diabetes patients. Basic Clin Pharmacol Toxicol 2011;109:481-485
43. Lu X, Guo X, Karathanasis SK, et al. Rosiglitazone reverses endothelial dysfunction but not remodeling of femoral artery in Zucker diabetic fatty rats. Cardiovasc Diabetol 2010;9:19